Please ensure Javascript is enabled for purposes of website accessibility

Is Inovio Worth Buying During the Market Correction?

By Alex Carchidi – Sep 26, 2020 at 7:36AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're into underdogs, you might want to add this pharmaceutical company to your portfolio.

Inovio Pharmaceuticals (INO 5.70%) has been one of 2020's hottest coronavirus vaccine stocks. At one point, it was trading 10 times higher than it began the year, due largely to the speed at which it moved its COVID-19 vaccine candidate through the development process and into phase 1 clinical trials.

Now, Inovio shares are nowhere near the peak they hit in June, and the stock appears to be sliding yet again as the broader market withdraws from its summer highs. Does that mean that this is a good time to buy Inovio at a relative discount, or is the company still vulnerable to a wider downturn in the market even if hype continues to build for its coronavirus vaccine candidate, INO-4800? In other words, has anything changed about the company's situation since June that has improved its long-term prospects?

I'm of the opinion that Inovio will probably get hit hard by the ongoing market correction because the stock has shown high volatility even in the absence of news about the company or its competitors. But, with a combined phase 2/3 clinical trial for INO-4800 set to begin soon, it might have a solid chance of bouncing back with equal force. The last few months have also seen Inovio advance in several key areas that are important for its competitive positioning in this race, which means that buying the stock during this correction could be all the more worthwhile.

A candlestick-style stock chart.

Image source: Getty Images.

Inovio's capabilities have grown, but will it be enough to beat the competition?

Since submitting its phase 1 clinical trial data for INO-4800 earlier this year, Inovio has taken aggressive steps to boost its manufacturing capabilities in anticipation of mass-producing it. In September, Thermo Fisher (TMO 3.79%) agreed to produce about 100 million doses of the vaccine in 2021, contingent on its regulatory approval from the U.S. Food and Drug Administration (FDA) early in the year. The deal was the third of its kind for Inovio in recent months, and also the largest, but the company is still seeking additional manufacturing partners so it can meet the anticipated demand. 

And even with those deals signed, Inovio's manufacturing capacity is still much lower than that of companies with more advanced candidates like Moderna (MRNA 1.59%), which is aiming to produce between 500 million and 1 billion doses of its candidate, mRNA-1273, in 2021. So even if Inovio's vaccine is approved, the company will still need to do a lot of work to reach manufacturing parity with its most likely competitors if it wants to capture a significant portion of the market.

Then there's the matter of the clinical trials. In July, Inovio expanded its phase 1 trial cohort, adding 80 new participants to the original group of 40. While this was a positive change that indicated that management was eager to produce high-quality trial data, it still left the company's trial significantly smaller than several others. Despite receiving government funding to the tune of $71 million earlier in the year, it's highly likely that Inovio still doesn't have the resources it needs to conduct trials on the scale of its rivals.

SPY Chart

SPY data by YCharts

How Inovio could bounce back from a falling market

Inovio is due to announce the initiation of the next phase of INO-4800 clinical trials by the end of September. This stage will be pivotal, because it may be Inovio's chance to catch up to some of the other companies in the race. If the market's response to that announcement is anything like its response to the company's prior releases, the stock will rise on vaccine optimism. And, if the announcement coincides with a deeper correction, as may be in the works, Inovio could be spared the worst, or potentially grow while its competitors get hammered. Especially if other competitors need to pause their trials for any reason -- as AstraZeneca (AZN 2.86%) did, briefly, earlier in the month -- Inovio could reemerge as a front-runner. 

More importantly, moving INO-4800 into its combined phase 2/3 clinical trials will open the door for the company to request additional resources from both the U.S. government and nonprofit benefactors like the Bill and Melinda Gates Foundation. Given that Washington appears to be very willing to spend money in support of the coronavirus vaccine development effort, this situation is in fact quite likely. Inovio could use such infusions of funds to increase the scale of its trials, gain more manufacturing capacity, or both -- but its stock and operational capacity could both grow substantially either way when the news breaks.

In summary, Inovio is probably worth buying in the midst of this stock market correction. Between the imminent favorable tailwinds from its advancing vaccine project and its modest progress over the past few months, the company's future seems brighter than before. But investors should be cautious: Inovio's capabilities still lag those of its rivals, even if its stock rises substantially on upcoming good news.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals Stock Quote
Inovio Pharmaceuticals
INO
$2.04 (5.70%) $0.11
AstraZeneca Plc Stock Quote
AstraZeneca Plc
AZN
$67.97 (2.86%) $1.89
Thermo Fisher Scientific Stock Quote
Thermo Fisher Scientific
TMO
$560.22 (3.79%) $20.47
Moderna Stock Quote
Moderna
MRNA
$175.91 (1.59%) $2.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.